- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00965523
Study of E7389 for Advanced or Metastatic Breast Cancer
14 juli 2013 uppdaterad av: Eisai Co., Ltd.
Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred to as Study 221) of E7389 for advanced or relapsed breast cancer by intravenously administering E7389.
Studieöversikt
Detaljerad beskrivning
Study 224 (Extension Period) was designed to evaluate the safety and efficacy of E7389 by collecting data from subjects who continued receiving E7389 after being transferred from Study 221 (Core Period).
Thus, efficacy analyses performed in Study 221 were updated and reported with the additional data collected in Study 224.
Objective response rate (ORR) and the number of subjects with adverse events are reported as outcome measures because these were the outcome measures of Study 221 which is a main study in the combined data.
Also, safety analyses performed in Study 221 were updated and reported with the additional data collected in Study 224.
Studietyp
Interventionell
Inskrivning (Faktisk)
81
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Fukuoka, Japan
-
Kagoshima, Japan
-
-
Aichi
-
Nagoya, Aichi, Japan
-
-
Hiroshima
-
Kure, Hiroshima, Japan
-
-
Tokyo
-
Chuo, Tokyo, Japan
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
20 år till 74 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Kvinna
Beskrivning
Inclusion criteria:
- Female patients with histologically or cytologically confirmed breast cancer.
- Patients who have received prior chemotherapy including anthracycline and taxane.
- Patients aged 20 - 74 years when giving informed consent and who have given written voluntary consent for participating in this study before the completion of Study 221.
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.
- Patients with a measurable lesion.
- Patients with an expected survival of ≥ 3 months from the start of study drug therapy.
- Female patients in whom continued administration of E7389 following Study 221 will be useful.
- Patients who have met the criteria for starting the next cycle in Study 221.
Namely, patients who meet all of the following criteria:
- Neutrophil count >= 1,500 /µL
- Platelet count >= 100,000 /µL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 times the upper limit of normal (ULN) in the facility or <= 5 times ULN in patients with hepatic metastasis)
- Total bilirubin <= 1.5 times ULN
- Serum creatinine <= 1.5 times ULN
- Non-hematological toxicity <= Grade 2 (excluding disease-associated events and laboratory abnormalities without clinical symptoms)
Exclusion criteria:
- Patients with systemic infection with a fever (≥38.0°C).
- Patients with pleural effusion, ascites or pericardial fluid requiring drainage.
- Patients with brain metastasis presenting clinical symptoms.
- Pregnant women, nursing mothers, or premenopausal women of childbearing potential. Premenopausal women of childbearing potential are defined as women who are <12 months after the latest menstruation and are positive in pregnancy test performed for enrollment or who have not taken the test and do not consent to take an appropriate contraceptive measure. Post-menopausal women must be amenorrheic for at least 12 months to make sure that they have no potential for becoming pregnant.
Patients with serious complications:
- Patients with uncontrollable cardiac disease such as ischemic heart disease and arrhythmia at a level of severity that needs to be treated (excluding left ventricular hypertrophy, mild left ventricular volume overload and mild right leg block that accompany hypertension)
- Patients with myocardial infarction within 6 months prior to study entry
- Patients with a complication of hepatic cirrhosis
- Patients with interstitial pneumonia and pulmonary fibrosis
- Patients with a bleeding tendency
- Patients with an active double cancer.
- Pregnant women or nursing mothers.
- Patients who have received extensive radiotherapy (≥30% of bone marrow).
- Patients who refuse to receive the supportive therapy of blood transfusion for myelosuppression.
- Patients who are participating in other clinical studies.
- Patients who are judged by the principal investigator or the other investigators to be inappropriate as patients in this clinical study.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Eribulin Mesylate
|
Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Number of Subjects With Adverse Events.
Tidsram: Every week during treatment and up to 30 days after last dose of study treatment
|
Every week during treatment and up to 30 days after last dose of study treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST)
Tidsram: Every 6 weeks
|
Objective response measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria and is Complete Response (disappearance of all target lesions) plus Partial Response (at least 30% decrease in sum of longest diameter [LD] of target lesions compared baseline sum of LD).
Tumor assessments every 6 weeks.
|
Every 6 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Tatsuo Watanabe, Oncology Clinical Development Section. JAC PCU., Eisai, Co., Ltd
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 januari 2008
Primärt slutförande (Faktisk)
1 december 2010
Avslutad studie (Faktisk)
1 januari 2011
Studieregistreringsdatum
Först inskickad
20 augusti 2009
Först inskickad som uppfyllde QC-kriterierna
24 augusti 2009
Första postat (Uppskatta)
25 augusti 2009
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
15 augusti 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 juli 2013
Senast verifierad
1 juli 2013
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- E7389-J081-224
- E7389-J081-221
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på Eribulin Mesylate
-
Oncologia Medica dell'Ospedale FatebenefratelliMario Negri Institute for Pharmacological ResearchAvslutadMetastaserad bröstcancer | Giftighet | Neurotoxicitet | Negativ droghändelse | LäkemedelstoxicitetItalien
-
IlDong Pharmaceutical Co LtdAvslutadFriskaKorea, Republiken av
-
Eisai GmbHAvslutadLokalt avancerad eller metastaserad bröstcancerTyskland
-
Calgent Biotechnology Co., LtdAvslutadResistenta eller eldfasta fasta tumörerFörenta staterna, Taiwan
-
Pathway Therapeutics, Inc.Avslutad
-
Fudan UniversityHar inte rekryterat ännu
-
Zhejiang Cancer HospitalHar inte rekryterat ännu
-
Henan Cancer HospitalRekryteringHR Positiv HER2 Negativ Avancerad BröstcancerKina
-
Massachusetts General HospitalEisai Inc.Aktiv, inte rekryterandeAngiosarkom | Epiteloid HemangioendoteliomFörenta staterna
-
Institut Cancerologie de l'OuestAvslutad